1. Home
  2. ORBS vs IFRX Comparison

ORBS vs IFRX Comparison

Compare ORBS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eightco Holdings Inc.

ORBS

Eightco Holdings Inc.

HOLD

Current Price

$0.60

Market Cap

262.0M

Sector

N/A

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.74

Market Cap

303.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORBS
IFRX
Founded
1966
2007
Country
United States
Germany
Employees
9
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
262.0M
303.4M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
ORBS
IFRX
Price
$0.60
$1.74
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$6.25
AVG Volume (30 Days)
11.9M
1.3M
Earning Date
04-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.74
52 Week High
$15.96
$2.95

Technical Indicators

Market Signals
Indicator
ORBS
IFRX
Relative Strength Index (RSI) 37.44 36.03
Support Level N/A $0.87
Resistance Level $1.23 $1.94
Average True Range (ATR) 0.05 0.15
MACD 0.00 -0.04
Stochastic Oscillator 21.37 3.97

Price Performance

Historical Comparison
ORBS
IFRX

About ORBS Eightco Holdings Inc.

Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business. Corrugated Packaging Business manufactured and sold custom packaging for a wide products and through packaging helps customers generate brand awareness and promote brand image. Generate the substantial majority of revenues from inventory financing and inventory management services.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: